BJMO - volume 13, issue 8, december 2019
K. Papadimitriou MD, PhD, M. Peeters MD, PhD, H. Prenen MD, PhD
This report will focus on some of the key studies in the field of digestive oncology, presented during the 2019 annual ESMO meeting. During the congress, many studies were presented from early phase I to large phase III trials. Different approaches to activate the immune system against tumours as well as PARP and CDK4/6 inhibitors were once more at the centre of interest for different types of cancer and settings.
Read moreBJMO - volume 13, issue 8, december 2019
P. Specenier MD, PhD
During the 2019 annual meeting of the European Society for Medical Oncology (ESMO) the most recent advances in recurrent/metastatic (R/M) and locoregionally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC) as well as nasopharyngeal carcinoma were discussed. In R/M HNSCC the safety and efficacy of monalizumab alone and in combination with cetuximab was assessed and the ELAN trials tried to assess the management of elderly HNSCC patients. In LA HNSCC the efficacy of Debio 1143 in combination with chemoradiotherapy as well as the dominance of cisplatin over cetuximab in association with radiotherapy were studied. In nasopharyngeal carcinoma, results were presented on the benefit of radiotherapy to chemotherapy with cisplatin and fluorouracil. Finally, Bossi et al. demonstrated that in non-endemic countries, patients with nasopharyngeal carcinoma have the same survival figures and prognostic factors as patients in endemic areas.
Read moreBJMO - volume 13, issue 8, december 2019
D. De Maeseneer MD, E. Werbrouck MD, S. De Keukeleire MSc, S. Rottey MD, PhD
In recent years, innovations in renal, bladder and prostate cancer treatments have been introduced at a rapid pace. Every year, oncological societies had to update treatment guidelines according to new insights and results of large phase III trials. This article focuses on practice changing data from the 2019 ESMO congress in Barcelona, Spain.
Read moreBJMO - volume 13, issue 8, december 2019
G. El Hachem MD, J. Kerger MD
After last year’s ESMO meeting in Munich, the recent ESMO Congress in Barcelona again proved to be a ‘grand cru’ in gynaecological cancer, with the confirmation of the role of maintenance therapy with PARP inhibitors in first-line therapy of advanced ovarian cancer, even beyond BRCA mutation. Additionally, recent progress in the management of endometrial and cervical cancer will be highlighted in this overview.
Read moreBJMO - volume 13, issue 8, december 2019
J. Blokken PhD, PharmD, Tom Feys MBA, MSc
The introduction of immune checkpoint inhibitors highly impacted the treatment landscape of melanoma over the last decade. At ESMO 2019, several abstracts again proved the clinical potential of these agents in the treatment of melanoma, both in (neo)adjuvant as in the advanced setting. In addition to this, promising results were presented with talimogene laherparepvec in early and in metastatic melanoma. Finally, several abstracts also discussed combinations of targeted agents and immunotherapy in patients with advanced melanoma.
Read moreBJMO - volume 13, issue 7, november 2019
Tom Feys MBA, MSc
From 7–10th of September, the 2019 World Conference on Lung Cancer (WCLC) again proved to be the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. The meeting attracted more than 7,000 specialists from more than 100 countries. In this highlight report ten top abstracts presented at the meeting will be discussed. For a more complete coverage of the meeting we refer to the congress website: https://wclc2019.iaslc.org.
(BELG J MED ONCOL 2019;13(7):309–13)
Read moreBJMO - volume 13, issue 7, november 2019
H. Van Poppel MD, PhD
The European Association of Urology (EAU) held its 34th Annual Congress in Barcelona from the 15–19th of March, a recurring highlight for the Association and for urology in general. While the presenting of the latest EAU Guidelines, holding meetings for its Board and Sections and setting agendas for the coming year are essential to the running of the Association, it is the latest scientific developments in urology that took centre stage in Barcelona.
Scientific Congress Office Chairman Prof Arnulf Stenzl (DE) presided over the scientific programme one last time, stepping down to join the EAU Executive as Adjunct Secretary General (Science). He was congratulated on his track record and particularly the comprehensive and diverse five-day programme that greeted the nearly 12,000 participants from 127 countries in Barcelona.
This article provides some uro-oncological highlights from the 263 different scientific sessions at EAU19. For the most complete coverage, see the on-site news reports on www.eau19.org/news.
(BELG J MED ONCOL 2019;13(7):314–6)
Read more
Top
